Intermediate Risk Prostate Cancer: Treatment Options Explained (MUSC)

Added:

Defining Risk
Surgical Path
Seed Implant
Beam Therapy
Side Effects
Rare Risks
Combining Care
Hormone Aid
Therapy Effects
Making Choice

Defining Risk

0:06
Playing Section
  • 1

    Categorizes prostate cancer as intermediate based on Gleason score or PSA levels.

  • 2

    Establishes high cure rates and low mortality for all treatment options.

  • 3

    Outlines three primary management approaches: surgery, seeds, and external beam.

Basic anatomy and physiological function of the prostate gland and surrounding pelvic organs.
The fundamentals of prostate cancer staging and risk stratification, including how Prostate-Specific Antigen (PSA) levels, Gleason Scores, and clinical T-stages are determined.
Basic medical terminology associated with cancer interventions, such as local therapy (surgery, radiation) versus systemic therapy.
The clinical distinction between active surveillance, watchful waiting, and active treatment strategies.
Comparative efficacy and long-term outcomes of robotic-assisted radical prostatectomy versus modern radiation modalities (e.g., SBRT, proton beam therapy).
The role of genomic classifiers and molecular profiling (e.g., Decipher, Prolaris) in refining intermediate-risk prostate cancer treatment decisions.
Advanced management of treatment-related toxicities, including pelvic floor rehabilitation for urinary incontinence and erectile dysfunction therapies.
The mechanism of action and side effect profile of androgen deprivation therapy (ADT) when combined with radiation for unfavorable intermediate-risk patients.
70.6K views915likes18:58@muschollingsOriginal Release: 2023-09-11

Intermediate risk prostate cancer, characterized by a Gleason score of 7 or PSA between 10-20, has three primary treatment options: radical prostatectomy (surgical removal with 5-15% incontinence risk), external beam radiation therapy (20 daily treatments over 4 weeks), and brachytherapy (seed implant done in one outpatient session); all options have high cure rates (~80-85%) with minimal mortality risk, though unfavorable intermediate risk patients (Gleason 4+3, PSA >10, or >50% positive cores) benefit from combining radiation with 4-6 months of hormonal therapy to improve cancer control and reduce recurrence risk.